102 related articles for article (PubMed ID: 22780098)
1. Chitosan-based intragastric delivery of cefuroxime axetil: development and in-vitro evaluation of mucoadhesive approach.
Nagar M; Yadav AV
Artif Cells Blood Substit Immobil Biotechnol; 2012 Dec; 40(6):406-18. PubMed ID: 22780098
[TBL] [Abstract][Full Text] [Related]
2. Preparation and evaluation of cefuroxime axetil gastro-retentive floating drug delivery system via hot melt extrusion technology.
Lalge R; Thipsay P; Shankar VK; Maurya A; Pimparade M; Bandari S; Zhang F; Murthy SN; Repka MA
Int J Pharm; 2019 Jul; 566():520-531. PubMed ID: 31185262
[TBL] [Abstract][Full Text] [Related]
3. Intragastric floating drug delivery system of cefuroxime axetil: in vitro evaluation.
Patel VF; Patel NM
AAPS PharmSciTech; 2006 Feb; 7(1):E17. PubMed ID: 16584147
[TBL] [Abstract][Full Text] [Related]
4. Design and characterization of cefuroxime axetil biphasic floating minitablets.
Jammula S; Patra ChN; Swain S; Panigrahi KC; Nayak S; Dinda SC; Rao ME
Drug Deliv; 2015 Jan; 22(1):125-35. PubMed ID: 24417642
[TBL] [Abstract][Full Text] [Related]
5. Development of gastroretentive drug delivery system for cefuroxime axetil: in vitro and in vivo evaluation in human volunteers.
Bomma R; Veerabrahma K
Pharm Dev Technol; 2013; 18(5):1230-7. PubMed ID: 22348334
[TBL] [Abstract][Full Text] [Related]
6. Optimization and Evaluation of Gastroretentive Ranitidine HCl Microspheres by Using Factorial Design with Improved Bioavailability and Mucosal Integrity in Ulcer Model.
Khattab A; Zaki N
AAPS PharmSciTech; 2017 May; 18(4):957-973. PubMed ID: 28271373
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerance of cefuroxime axetil: an overview of the Italian experience.
Lechi A; Ghidini O; Dal Negro R; Cattini GC; Bezzi E
J Chemother; 1989 Jul; 1(4 Suppl):646-7. PubMed ID: 16312573
[No Abstract] [Full Text] [Related]
8. Preparation and in vitro evaluation of chitosan microgranules with clotrimazole.
Szymańska E; Winnicka K
Acta Pol Pharm; 2012; 69(3):509-13. PubMed ID: 22594265
[TBL] [Abstract][Full Text] [Related]
9. Co-processing of cefuroxime axetil by spray drying technique for improving compressibility and flow property.
Rathod P; Mori D; Parmar R; Soniwala M; Chavda J
Drug Dev Ind Pharm; 2019 May; 45(5):767-774. PubMed ID: 30722705
[TBL] [Abstract][Full Text] [Related]
10. Optimization of particle size and encapsulation efficiency of vancomycin nanoparticles by response surface methodology.
Honary S; Ebrahimi P; Hadianamrei R
Pharm Dev Technol; 2014 Dec; 19(8):987-98. PubMed ID: 24147898
[TBL] [Abstract][Full Text] [Related]
11. A multicenter trial comparing the efficacy and safety of cefuroxime axetil and cefaclor in pneumonia of adults.
Yangco BG; Lowe J; Nolen TM; Schleupner C; Tan JS; Anthony W
Clin Ther; 1990; 12(5):440-6. PubMed ID: 2268867
[TBL] [Abstract][Full Text] [Related]
12. Ionotropic cross-linked chitosan microspheres for controlled release of ampicillin.
Anal AK; Stevens WF; Remuñán-López C
Int J Pharm; 2006 Apr; 312(1-2):166-73. PubMed ID: 16497452
[TBL] [Abstract][Full Text] [Related]
13. Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability.
Dhumal RS; Biradar SV; Aher S; Paradkar AR
J Pharm Pharmacol; 2009 Jun; 61(6):743-51. PubMed ID: 19505364
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults.
Siegert R; Berg O; Gehanno P; Leiberman A; Martinkenas JL; Nikolaidis P; Arvis P; Alefelder M; Reimnitz P
Eur Arch Otorhinolaryngol; 2003 Apr; 260(4):186-94. PubMed ID: 12709801
[TBL] [Abstract][Full Text] [Related]
15. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.
Sommers DK; van Wyk M; Moncrieff J; Schoeman HS
Br J Clin Pharmacol; 1984 Oct; 18(4):535-9. PubMed ID: 6091711
[TBL] [Abstract][Full Text] [Related]
16. [Studies on the action features between cefuroxime axetil and bovine serum albumin].
Wu GK; Yan CN; Liu Y
Guang Pu Xue Yu Guang Pu Fen Xi; 2008 Sep; 28(9):2139-43. PubMed ID: 19093579
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of cefuroxime axetil formulations.
Donn KH; James NC; Powell JR
J Pharm Sci; 1994 Jun; 83(6):842-4. PubMed ID: 9120818
[TBL] [Abstract][Full Text] [Related]
18. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability.
Dhumal RS; Biradar SV; Yamamura S; Paradkar AR; York P
Eur J Pharm Biopharm; 2008 Sep; 70(1):109-15. PubMed ID: 18502628
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability of cefuroxime axetil suspension formulations administered with food in healthy subjects.
Mendes GD; Borges A; de Cássia Val L; Patni AK; Reyar S; Monif T; Sereno D; Orellana AM; De Nucci G
Arzneimittelforschung; 2010; 60(2):101-5. PubMed ID: 20329659
[TBL] [Abstract][Full Text] [Related]
20. Tissue penetration following orally administered cefuroxime axetil.
Wise R
J Chemother; 1989 Jul; 1(4 Suppl):515-6. PubMed ID: 16312510
[No Abstract] [Full Text] [Related]
[Next] [New Search]
